1 A cautionary note on recall vaccination in ex-COVID-19 subjects 2 Riccardo Levi, MSc*1,2, Elena Azzolini, MD PhD*1,2, Chiara Pozzi, PhD*2, Leonardo Ubaldi, MSc1*, 3 Michele Lagioia², MD, Alberto Mantovani, MD^{1, 2, 3} and Maria Rescigno, PhD^{1, 2, #} 4 5 6 ¹Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 7 Pieve Emanuele, Milan, Italy. 8 ²IRCSS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy. 9 ³The William Harvey Research Institute, Queen Mary University of London, London, UK 10 11 *These authors contributed equally 12 13 14 15 *Corresponding author: 16 E-mail: maria.rescigno@hunimed.eu 17 **Humanitas University** 18 Via Rita Levi Montalcini, 4 19 20090 Pieve Emanuele (Mi) Italy

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

Abstract Currently approved COVID-19 vaccines based on mRNA or adenovirus require a first jab followed by recall immunization. There is no indication as to whether individuals who have recovered from COVID-19 should be vaccinated, and if so, if they should receive one or two vaccine doses. Here, we tested the antibody response developed after the first dose of the mRNA based vaccine encoding the SARS-CoV-2 full-length spike protein (BNT162b2) in 124 healthcare professionals of which 57 had a previous history of COVID-19 (ExCOVID). Post-vaccine antibodies in ExCOVID individuals increase exponentially within 7-15 days after the first dose compared to naïve subjects (p<0.0001). We developed a multivariate Linear Regression (LR) model with 12 regularization to predict the IgG response for SARS-COV-2 vaccine. We found that the antibody response of ExCOVID patients depends on the IgG pre-vaccine titer and on the symptoms that they developed during the disorder, with anosmia/dysgeusia and gastrointestinal disorders being the most significantly positively correlated in the LR. Thus, one vaccine dose is sufficient to induce a good antibody response in ExCOVID subjects. This poses caution for ExCOVID subjects to receive a second jab both because they may have a overreaction of the inflammatory response and also in light of the current vaccine shortage. Introduction Currently approved COVID-19 vaccines based on mRNA 1-3 or adenovirus 4 require a first jab followed by recall immunization. The impact of previous exposure to SARS-CoV-2 on immune response elicited the vaccines has not been assessed. Methods We tested the antibody response developed after the first dose of the mRNA based vaccine encoding the SARS-CoV-2 full-length spike protein (BNT162b2)¹ in 124 healthcare professionals of which 57 had a previous history of COVID-19 (ExCOVID) (Table 1), as part of an observational study (clinicaltrial.gov NCT04387929) conducted at Istituto Clinico Humanitas in which healthcare

professionals were followed for serology and for any occurring COVID-19 related symptoms every three months⁵. We recorded the antibody response to Spike 1/2 with a quantitative test (Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Italy) which allowed us to evaluate even large amounts of plasma IqG. To predict the IqG response for SARS-COV-2 vaccine, a multivariate Linear Regression (LR) model with I2 regularization (also known as Ridge Regression) was developed. Numerical variables were standardized (z-score algorithm) and the target variable was log transformed due to right asymmetry of the distribution. The subjects without the serological analysis before vaccination were excluded from this analysis (n=11). The final number of subjects analyzed in LR was 113. Results As shown in Fig.1A-B ExCOVID individuals had a much higher antibody response after the first dose of vaccine than naïve subjects (p<0.0001), regardless of when they developed the COVID-19. They displayed an exponential increase of anti-Spike 1/2 antibody response within 7-15 days after the first dose of vaccine. The pre-vaccine antibody amount of the ExCOVID population was on average 44.+/-37.7 while that after the vaccine was 1055.7+/-1004.2 (p<0.0001) (Table 1), with higher levels in symptomatic ExCOVID (Fig. 1C, p=0.028). We investigated the relationship between the amount of IgG after vaccination with COVID-19, sex, age and symptoms related to disease. The final LR shows a good prediction of the target variable $(R^2=0.88, F-statistic = 39.18, p-value<0.001)$ and the most significant features were history of COVID-19 (1.48, 95% CI 1.07-1.93), the value of IgG before vaccination (0.87, 95% CI 0.59-1.13), the difference between the date of vaccination and the date of serology post-vax (0.87, 95% CI 0.65-1.03), and age (-0.13, 95% CI -0.24 - -0.001) as well as COVID-19 related symptoms: gastrointestinal disorders (0.59, 95% CI 0.16-0.97), anosmia/dysgeusia (0.50, 95% CI 0.14-0.87), tachycardia (0.26, 95% CI 0.02-0.60) and sore throat (-0.35, 95% CI -0.53 - -0.11) (Fig. 1D, Suppl. Table1).

Discussion

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

The antibody response of ExCOVID patients depends on the IgG pre-vaccine titer and on the symptoms that they developed during the disorder, with anosmia/dysgeusia and gastrointestinal disorders being the most significantly positively correlated in the LR, while sore throat was negatively correlated because 45% non-COVID individuals reported it. Young subjects had a higher antibody response. We previously observed that anosmia/dysgeusia was associated with an increase of antibodies over time, independently of vaccination (Levi et al. submitted). Thus, one vaccine dose is sufficient to induce a good antibody response in ExCOVID subjects and poses caution for a second dose: over stimulation with high amount of antigens could switch-off the immune response due to antigen exhaustion, which occurs in response to several viruses (reviewed in⁶). Alternatively, overactivation of the immune response may drive the development of low-affinity antibodies for SARS-CoV-2 which may foster an antibody dependent enhancement (ADE) reaction when re-exposed to the virus (reviewed in⁷). These results question whether a second shot in ExCOVID subjects is indeed required and suggest to post-pone it while monitoring antibody response longevity. At a time of vaccine scarcity, these findings may have public health implications.

References

- 96 1. Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and Immunogenicity of Two RNA-
- 97 Based Covid-19 Vaccine Candidates. *N Engl J Med.* 2020;383(25):2439-2450.
- 98 2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
- 99 Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615.
- 100 3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-
- 101 CoV-2 Vaccine. N Engl J Med. 2020.

102 4. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 103 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised 104 controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. 105 5. Sandri MT, Azzolini E, Torri V, et al. SARS-CoV-2 serology in 4000 health care and 106 administrative staff across seven sites in Lombardy, Italy. medRxiv. 107 2020:2020.2005.2024.20111245. 108 Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. 6. 109 Immunology. 2010;129(4):474-481. 110 7. Flanagan KL, Best E, Crawford NW, et al. Progress and Pitfalls in the Quest for Effective 111 SARS-CoV-2 (COVID-19) Vaccines. Front Immunol. 2020;11:579250. 112 113

A

			Serology pre VAX								
			counts	%	min	max	mean	std	TEST	p	
	COVID-19	NO (Healthy)	67	59.29	3	7.66	3.35	1.02	MW	5E-12	
		YES (ExCOVID)	46	40.71	3	140	44.58	37.72	101 00	JE-12	
	GENDER	F	63	55.75	3	132	18.86	28.46	MW	0.295	
		M	50	44.25	3	140	21.74	34.99	171 77	0.293	
	Age_class	21-30	24	21.24	3	140	29.25	38.82	MW	0.027	
		31-40	37	32.74	3	132	16.56	28.14	MW	0.086	
		41-50	31	27.43	3	81.7	14.76	22.91	MW	0.074	
		51-60	13	11.5	3	123	25.73	42.37	KS	0.146	
		60+	8	7.08	3	78.1	21.12	29.81	KS	0.986	

В			Serology post VAX								
				%	min	max	mean	std	TEST	p	
	COVID-19	NO (Healthy)	67	54.03	3	104	13.29	19.73	MW	3E-19	
	COVID-19	YES (ExCOVID)	57	45.97	3	4000	1055.7	1004.2	IVI VV	3E-19	
	GENDER	\mathbf{F}	71	57.26	3	3800	466.97	875.9	MW	0.455	
	GENDER	M	53	42.74	3	4000	526.62	833.75	IVI VV	0.433	
		21-30	30	24.19	3	4000	601.13	901.65	MW	0.015	
		31-40	39	31.45	3	3800	553.52	1046.9	MW	0.115	
	Age_class	41-50	33	26.61	3	2320	351.12	644.59	MW	0.234	
		51-60	14	11.29	3	2240	437.95	740.98	KS	0.986	
		60+	8	6.45	3	1690	465.76	664.78	KS	0.696	
	CLASS SYMPTOMS	a/paucisymptomatic	15	26.32	3	1800	507.73	598.39	KS	0.029	
	(for ExCOVID)	symptomatic	42	73.68	10.7	4000	1251.4	1051.6	KS	0.029	
	Fever	0	30	52.63	3	3800	865.65	942.76	MW	0.034	
		1	27	47.37	10.7	4000	1266.9	1045.2		0.034	
	Low-grade Fever	0	44	77.19	3	4000	954.8	1060.1	KS	0.016	
		1	13	22.81	27	2630	1397.2	717.47		0.010	
	Headache	0	31	54.39	3	2520	825.63	734.51	MW	0.038	
		1	26	45.61	27	4000	1330	1211.4			
	Cough	0	40	70.18	3	3800	921.12	959.53	KS	0.176	
		1	17	29.82	8.18	4000	1372.4	1064.5			
	Sore throath	0	31	54.39	3	3330	1040.9	857.41	MW	0.365	
ExCOVID		1	26	45.61	8.18	4000	1073.4	1173			
EXCOVID	Muscle pain	0	27	47.37	3	4000	864.43	1100.9	MW	0.013	
	Wuscie pain	1	30	52.63	10.7	3330	1227.9	892.15	171 77	0.013	
	Asthenia	0	25	43.86	3	2520	717.64	784.71	MW	0.008	
	Astricina	1	32	56.14	10.7	4000	1319.8	1086.6	171 77	0.000	
	Anosmia/dysgeusia	0	29	50.88	3	4000	824.28	1044.4	MW	0.009	
	Anosima/uysgeusia	1	28	49.12	27	3800	1295.4	918.26		0.009	
	Gastrointestinal	0	33	57.89	8.18	2520	902.12	753.36		0.212	
	disorders	1	24	42.11	3	4000	1266.9	1259		0.212	
	Conjunctivitis	0	49	85.96	3	4000	1018.2	984.56	KS	0.896	
		1	8	14.04	27	3330	1285.8	1161.6	KS	0.070	
									·		

				_						
	Dyspnea	0	41	71.93	3	4000	952.52	1017.5	KS	0.179
	Бузриса	1	16	28.07	27	3330	1320.1	948.76	K)	0.179
	Chest pain	0	42	73.68	3	4000	989.3	988.56	VC	0.910
		1	15	26.32	27	3330	1241.6	1058.9	KS	0.819
	T	0	47	82.46	3	3800	982.11	870.62	IZC.	0.395
	Tachycardia	1	10	17.54	27	4000	1401.6	1496.3	KS	
	Pneumonia	0	50	87.72	3	4000	1013.9	1036.5	KS	0.218
	1 neumoma	1	7	12.28	27	2240	1354.3	720.25	K)	
	Fever	0	63	94.03	3	104	13.45	20.13	KS	0.005
	rever	1	4	5.97	3	30.7	10.74	13.4	K)	0.995
	Low-grade Fever	0	62	92.54	3	104	14.04	20.33	VC	0.559
	Low-grade rever	1	5	7.46	3	6.26	3.9	1.42	KS	0.555
	Handa sha	0	42	62.69	3	104	12.68	20.73	MW	0.438
	Headache	1	25	37.31	3	60.5	14.3	18.28		
	Cough	0	51	76.12	3	104	12.52	20.12	KS	0.126
	Cougn	1	16	23.88	3	63.8	15.72	18.85		
	Como 4h moo4h	0	37	55.22	3	60.5	11.02	15.69	MW	0.256
	Sore throath	1	30	44.78	3	104	16.08	23.78	MW	0.230
	Mussla nain	0	58	86.57	3	104	12.54	19.49	KS	0.724
	Muscle pain	1	9	13.43	3	55.9	18.11	21.79	N.o	0.724
	Asthenia	0	56	83.58	3	104	12.23	19.47	KS	0.419
Healthy	Astriema	1	11	16.42	3	49.7	18.68	21.11	Ko	0.415
пеанну	Anosmia/dysgeusia	0	66	98.51	3	104	13.4	19.86	V.C	0.687
	Anosima/uysgeusia	1	1	1.49	6.13	6.13	6.13		KS	0.067
	Gastrointestinal	0	58	86.57	3	104	13.3	20.1	KS	0.656
	disorders	1	9	13.43	3	55.9	13.2	18.24	N.S	
	Conjunctivitis	0	60	89.55	3	63.8	11.5	16.12	KS	0.419
	Conjunctivitis	1	7	10.45	3	104	28.62	37.68	N.S	
	Dycnnes	0	64	95.52	3	104	13.75	20.07	KS	0.399
	Dyspnea	1	3	4.48	3	4.5	3.5	0.87	NO.	0.399
	Chest pain	0	63	94.03	3	104	13.92	20.19	KS	0.205
		1	4	5.97	3	4.4	3.35	0.7	NO.	
	Tachycardia	0	62	92.54	3	104	14.07	20.32	KS	0.195
	i acii y cai ui a	1	5	7.46	3	4.57	3.61	0.84	110	0.195
	Pneumonia	0	67	100	3	104	13.29	19.73	na	n
	1 iicumoma	1	0	0	0	0	0	0	1144	na

			%	min	max	mean	std	TEST	p	
Days between VAX and serology post VAX	Healthy	67	54.03	4.8	16.9	8.9	2.91	MW	3E-08	
	ExCOVID	57	45.97	4.89	20.4	13.81	4.91			

Table 1. A.B. Demographic distribution of anti-Spike 1/2 IgG plasma levels. C. Days between vaccination and serology post vaccination. *P* values determined using two-tailed unpaired Mann–Whitney test (MW) or two-tailed unpaired Kolmogorov-Smirnov test (KS). NA: not applicable.




Figure 1: ExCOVID subjects increase exponentially anti-Spike 1/2 IgG levels after the first dose of vaccine. A, anti-Spike 1/2 IgG plasma levels in healthy (n=67) and ExCOVID individuals (n=57) measured after the first dose of vaccine. B, anti-Spike 1/2 IgG plasma levels in healthy (n=67) and ExCOVID individuals (n=46) measured before and after the first dose of vaccine. C, anti-Spike 1/2 IgG plasma levels in asymptomatic / paucisymptomatic (n=15) and in symptomatic (n=42) ExCOVID individuals measured after the first dose of vaccine. D, Multivariate linear regression coefficients for the most significant variables (*p*<0.05). Dot points represent the mean values and the lines the 95% CI.

The box plots (A, C) show the interquartile range, the horizontal lines show the median values and the whiskers indicate the minimum-to-maximum range. *P* values were determined using two-tailed unpaired Mann–Whitney test (A) or two-tailed Wilcoxon matched-pairs signed rank test (B) or two-tailed unpaired Kolmogorov-Smirnov test (C).